BiotechTube

YM155

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Nov 1, 2005 → Jun 1, 2007

NCT ID
NCT00281541

About YM155

YM155 is a phase 2 stage product being developed by Astellas Pharma for Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00281541. Target conditions include Melanoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT00257478Phase 2Completed
NCT01023386Phase 1Completed
NCT00498914Phase 2Terminated
NCT00328588Phase 2Completed
NCT00818480Phase 2Completed
NCT00281541Phase 2Completed

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
25
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
FYB206 + KeytrudaFormycon AGPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41
E7386 + Pembrolizumab + LenvatinibEisaiPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85